An examination of Overactive Bladder Syndrome: present comprehension, methods of treatment, and innovative approaches
DOI:
https://doi.org/10.12775/JEHS.2024.64.007Keywords
overactive bladder, urgency urinary incontinence, anticholinergics, mirabegron, nocturiaAbstract
Introduction
Overactive bladder syndrome poses a major challenge to healthcare, as an accurate estimate of its prevalence proves elusive due to patients' reluctance to disclose the embarrassing symptoms that accompany the disorder. Symptoms such as frequent urination, nocturia and incontinence are not only distressing but also significantly impair patients' quality of life. Effective diagnosis and treatment require the identification of associated risk factors, and behavioural therapy serves as the basis for implementing lifestyle modifications. This comprehensive study delves into the managing of overactive bladder syndrome, shedding light on recent advances in diagnosis and treatment. In particular, it looks at the integration of minimally invasive techniques and new medications that promise to not only alleviate symptoms, but also significantly improve patients' overall quality of life.
Aim of the study
This review aims to identify risk factors, symptoms, methods of diagnosis of overactive bladder syndrome and solutions in its treatment process. The main aim is to present treatment methods with the latest developments.
Material and method
This article presents the current state of knowledge about overactive bladder syndrome in various scientific articles. Publications describing overactive bladder syndrome, its symptoms, impact on life comfort and treatment options, including recent reports in the field, were reviewed using the PubMed platform. The search included the keywords ‘overactive bladder’, ‘urgency urinary incontinence’, ‘anticholinergics’, ‘mirabegron’, ‘nocturia’.
References
Wolff GF, Kuchel GA, Smith PP. Overactive bladder in the vulnerable elderly. Res Rep Urol. 2014 Oct 3;6:131-8. doi: 10.2147/RRU.S41843. PMID: 25328867; PMCID: PMC4199655.
Fontaine C, Papworth E, Pascoe J, Hashim H. Update on the management of overactive bladder. Ther Adv Urol. 2021 Aug 31;13:17562872211039034. doi: 10.1177/17562872211039034. PMID: 34484427; PMCID: PMC8411623.
Bartley JM, Blum ES, Sirls LT, Peters KM. Understanding clinic options for overactive bladder. Curr Urol Rep. 2013 Dec;14(6):541-8. doi: 10.1007/s11934-013-0353-6. PMID: 23812967.
Gormley EA, Lightner DJ, Faraday M, Vasavada SP; American Urological Association; Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015 May;193(5):1572-80. doi: 10.1016/j.juro.2015.01.087. Epub 2015 Jan 23. PMID: 25623739.
Hutchinson A, Nesbitt A, Joshi A, Clubb A, Perera M. Overactive bladder syndrome: Management and treatment options. Aust J Gen Pract. 2020 Sep;49(9):593-598. doi: 10.31128/AJGP-11-19-5142. PMID: 32864677.
Hsiao SM, Wu PC, Chang TC, Chen CH, Lin HH. Urodynamic and Bladder Diary Factors Predict Overactive Bladder-wet in Women: A Comparison With Overactive Bladder-dry. Int Neurourol J. 2019 Mar;23(1):69-74. doi: 10.5213/inj.1836212.106. Epub 2019 Mar 31. PMID: 30943696; PMCID: PMC6449656.
Jo JK, Lee S, Kim YT, Choi HY, Kim SA, Choi BY, Moon HS. Analysis of the risk factors for overactive bladder on the basis of a survey in the community. Korean J Urol. 2012 Aug;53(8):541-6. doi: 10.4111/kju.2012.53.8.541. Epub 2012 Aug 16. PMID: 22949998; PMCID: PMC3427838.
Dallosso HM, McGrother CW, Matthews RJ, Donaldson MM; Leicestershire MRC Incontinence Study Group. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BJU Int. 2003 Jul;92(1):69-77. doi: 10.1046/j.1464-410x.2003.04271.x. PMID: 12823386.
Dallosso HM, Matthews RJ, McGrother CW, Donaldson MM, Shaw C; Leicestershire MRC Incontinence Study Group. The association of diet and other lifestyle factors with the onset of overactive bladder: a longitudinal study in men. Public Health Nutr. 2004 Oct;7(7):885-91. doi: 10.1079/phn2004627. PMID: 15482614.
Corcos J, Przydacz M, Campeau L, Gray G, Hickling D, Honeine C, Radomski SB, Stothers L, Wagg A, Lond F. CUA guideline on adult overactive bladder. Can Urol Assoc J. 2017 May;11(5):E142-E173. doi: 10.5489/cuaj.4586. Epub 2017 May 9. Erratum in: Can Urol Assoc J. 2017 May;11(5):E250. Erratum in: Can Urol Assoc J. 2017 Jul;11(7):E323. PMID: 28503229; PMCID: PMC5426936.
Truzzi JC, Gomes CM, Bezerra CA, Plata IM, Campos J, Garrido GL, Almeida FG, Averbeck MA, Fornari A, Salazar A, Dell'Oro A, Cintra C, Sacomani CA, Tapia JP, Brambila E, Longo EM, Rocha FT, Coutinho F, Favre G, Garcia JA, Castano J, Reyes M, Leyton RE, Ferreira RS, Duran S, Lopez V, Reges R. Overactive bladder - 18 years - Part I. Int Braz J Urol. 2016 Mar-Apr;42(2):188-98. doi: 10.1590/S1677-5538.IBJU.2015.0365. PMID: 27176184; PMCID: PMC4871378.
Nicolson P, Kopp Z, Chapple CR, Kelleher C. It's just the worry about not being able to control it! A qualitative study of living with overactive bladder. Br J Health Psychol. 2008 May;13(Pt 2):343-59. doi: 10.1348/135910707X187786. Epub 2007 Mar 7. PMID: 17535499.
Gordon D, Groutz A. Evaluation of female lower urinary tract symptoms: overview and update. Curr Opin Obstet Gynecol. 2001 Oct;13(5):521-7. doi: 10.1097/00001703-200110000-00012. PMID: 11547034.
Srikrishna S, Robinson D, Cardozo L, Vella M. Management of overactive bladder syndrome. Postgrad Med J. 2007 Jul;83(981):481-6. doi: 10.1136/pgmj.2007.057232. PMID: 17621619; PMCID: PMC2600101.
Scarpero H. Urodynamics in the evaluation of female LUTS: when are they helpful and how do we use them? Urol Clin North Am. 2014 Aug;41(3):429-38, viii-ix. doi: 10.1016/j.ucl.2014.04.010. PMID: 25063599.
Bosch JL, Cardozo L, Hashim H, Hilton P, Oelke M, Robinson D. Constructing trials to show whether urodynamic studies are necessary in lower urinary tract dysfunction. Neurourol Urodyn. 2011 Jun;30(5):735-40. doi: 10.1002/nau.21130. PMID: 21661022.
Liu HT, Chen CY, Kuo HC. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders. J Formos Med Assoc. 2010 Dec;109(12):862-78. doi: 10.1016/S0929-6646(10)60133-7. PMID: 21195884.
Kreydin EI, Gomes CM, Cruz F. Current pharmacotherapy of overactive bladder. Int Braz J Urol. 2021 Nov-Dec;47(6):1091-1107. doi: 10.1590/S1677-5538.IBJU.2021.99.12. PMID: 34003613; PMCID: PMC8486454.
Borello-France D, Burgio KL, Goode PS, Markland AD, Kenton K, Balasubramanyam A, Stoddard AM; Urinary Incontinence Treatment Network. Adherence to behavioral interventions for urge incontinence when combined with drug therapy: adherence rates, barriers, and predictors. Phys Ther. 2010 Oct;90(10):1493-505. doi: 10.2522/ptj.20080387. Epub 2010 Jul 29. PMID: 20671098; PMCID: PMC2949583.
Markland AD, Vaughan CP, Johnson TM 2nd, Burgio KL, Goode PS. Incontinence. Med Clin North Am. 2011 May;95(3):539-54, x-xi. doi: 10.1016/j.mcna.2011.02.006. PMID: 21549877.
Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int. 2008 Jul;102(1):62-6. doi: 10.1111/j.1464-410X.2008.07463.x. Epub 2008 Feb 18. PMID: 18284414.
Swithinbank L, Hashim H, Abrams P. The effect of fluid intake on urinary symptoms in women. J Urol. 2005 Jul;174(1):187-9. doi: 10.1097/01.ju.0000162020.10447.31. PMID: 15947624.
Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM, Richter HE, Myers D, Burgio KL, Gorin AA, Macer J, Kusek JW, Grady D; PRIDE Investigators. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009 Jan 29;360(5):481-90. doi: 10.1056/NEJMoa0806375. PMID: 19179316; PMCID: PMC2877497.
Sellers DJ, Chess-Williams R. Muscarinic agonists and antagonists: effects on the urinary bladder. Handb Exp Pharmacol. 2012;(208):375-400. doi: 10.1007/978-3-642-23274-9_16. PMID: 22222707.
Ju R, Garrett J, Wu JM. Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States. Int Urogynecol J. 2014 Apr;25(4):479-84. doi: 10.1007/s00192-013-2246-0. Epub 2013 Oct 25. PMID: 24158462.
Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008 Sep;54(3):543-62. doi: 10.1016/j.eururo.2008.06.047. Epub 2008 Jun 20. PMID: 18599186.
Joseph S, Maria SA, Peedicayil J. Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review. Curr Ther Res Clin Exp. 2022 Apr 6;96:100669. doi: 10.1016/j.curtheres.2022.100669. PMID: 35494662; PMCID: PMC9052038.
Keam SJ. Vibegron: First Global Approval. Drugs. 2018 Nov;78(17):1835-1839. doi: 10.1007/s40265-018-1006-3. PMID: 30411311.
Cui Y, Zong H, Yang C, Yan H, Zhang Y. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol. 2014 Jan;46(1):275-84. doi: 10.1007/s11255-013-0509-9. Epub 2013 Jul 30. PMID: 23896942.
Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. Eur Urol. 2020 Jan;77(1):119-128. doi: 10.1016/j.eururo.2019.09.024. Epub 2019 Oct 18. PMID: 31635815.
Sartori LGF, Nunes BM, Farah D, Oliveira LM, Novoa CCT, Sartori MGF, Fonseca MCM. Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis. Rev Bras Ginecol Obstet. 2023 Jun;45(6):337-346. doi: 10.1055/s-0043-1770093. Epub 2023 Jul 21. PMID: 37494577; PMCID: PMC10371066.
Frankel J, Staskin D, Varano S, Kennelly MJ, Jankowich RA, Haag-Molkenteller C. An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder. Ther Clin Risk Manag. 2022 Mar 3;18:171-182. doi: 10.2147/TCRM.S310371. PMID: 35264853; PMCID: PMC8901416.
Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, Herschorn S, Saleem T, Huang M, Siddiqui E, Stölzel M, Herholdt C, MacDiarmid S; BESIDE study investigators. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. 2016 Jul;70(1):136-145. doi: 10.1016/j.eururo.2016.02.030. Epub 2016 Mar 8. PMID: 26965560.
Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J; Pelvic Floor Disorders Network. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008 Jul;180(1):217-22. doi: 10.1016/j.juro.2008.03.028. Epub 2008 May 21. PMID: 18499184; PMCID: PMC2597793.
Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013 Jun;189(6):2186-93. doi: 10.1016/j.juro.2012.12.022. Epub 2012 Dec 14. PMID: 23246476.
Nitti V, Haag-Molkenteller C, Kennelly M, Chancellor M, Jenkins B, Schurch B. Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Baltimore). 2023 Jul 1;102(S1):e32377. doi: 10.1097/MD.0000000000032377. PMID: 37499088; PMCID: PMC10374192.
Zhang Y, Meng L, Zhang P, Tian X, Chen G, Li Y, Zhang Y, Xu Z, Wei Z, Zhang W, Ma L, Shi B, Liao L, Wang J. Intermediate-term results of a prospective, multicenter study on remote programming sacral neuromodulation for refractory overactive bladder. Transl Androl Urol. 2021 May;10(5):1966-1975. doi: 10.21037/tau-21-43. PMID: 34159077; PMCID: PMC8185673.
Sukhu T, Kennelly MJ, Kurpad R. Sacral neuromodulation in overactive bladder: a review and current perspectives. Res Rep Urol. 2016 Oct 26;8:193-199. doi: 10.2147/RRU.S89544. PMID: 27822462; PMCID: PMC5087764.
Biemans JM, van Balken MR. Efficacy and effectiveness of percutaneous tibial nerve stimulation in the treatment of pelvic organ disorders: a systematic review. Neuromodulation. 2013 Jan-Feb;16(1):25-33; discussion 33. doi: 10.1111/j.1525-1403.2012.00504.x. Epub 2012 Sep 17. PMID: 22985128.
Bhide AA, Tailor V, Fernando R, Khullar V, Digesu GA. Posterior tibial nerve stimulation for overactive bladder-techniques and efficacy. Int Urogynecol J. 2020 May;31(5):865-870. doi: 10.1007/s00192-019-04186-3. Epub 2019 Dec 18. PMID: 31853597; PMCID: PMC7210232.
Yoong W, Ridout AE, Damodaram M, Dadswell R. Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes following a shortened 6-week protocol. BJU Int. 2010 Dec;106(11):1673-6. doi: 10.1111/j.1464-410X.2010.09461.x. PMID: 20590544.
Veeratterapillay R, Thorpe AC, Harding C. Augmentation cystoplasty: Contemporary indications, techniques and complications. Indian J Urol. 2013 Oct;29(4):322-7. doi: 10.4103/0970-1591.120114. PMID: 24235795; PMCID: PMC3822349.
Malysz J, Petkov GV. Urinary bladder smooth muscle ion channels: expression, function, and regulation in health and disease. Am J Physiol Renal Physiol. 2020 Aug 1;319(2):F257-F283. doi: 10.1152/ajprenal.00048.2020. Epub 2020 Jul 6. PMID: 32628539; PMCID: PMC7473901.
Matsuo T, Miyata Y, Araki K, Mukae Y, Otsubo A, Ohba K, Sakai H. Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder. Low Urin Tract Symptoms. 2020 Jan;12(1):47-53. doi: 10.1111/luts.12283. Epub 2019 Aug 13. PMID: 31407871; PMCID: PMC7004155.
Lee JJ, Heo JW, Choi TY, Jun JH, Lee MS, Kim JI. Acupuncture for the treatment of overactive bladder: A systematic review and meta-analysis. Front Neurol. 2023 Jan 12;13:985288. doi: 10.3389/fneur.2022.985288. PMID: 36712423; PMCID: PMC9878288.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Zuzanna Kotowicz, Jakub Pabiś, Piotr Podgórski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 333
Number of citations: 0